Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Rothenberg ML, et al. J Clin Oncol. 2003 Jun 1;21(11):2059-69. doi: 10.1200/JCO.2003.11.126. J Clin Oncol. 2003. PMID: 12775730 Clinical Trial.
Phase I and pharmacokinetic trial of weekly CPT-11.
Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, et al. Rothenberg ML, et al. J Clin Oncol. 1993 Nov;11(11):2194-204. doi: 10.1200/JCO.1993.11.11.2194. J Clin Oncol. 1993. PMID: 8229134 Clinical Trial.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Burris HA 3rd, et al. Among authors: rothenberg ml. J Clin Oncol. 1997 Jun;15(6):2403-13. doi: 10.1200/JCO.1997.15.6.2403. J Clin Oncol. 1997. PMID: 9196156 Clinical Trial.
Alternative dosing schedules for irinotecan.
Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. Rothenberg ML, et al. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71. Oncology (Williston Park). 1998. PMID: 9726095 Free article. Review.
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. Drengler RL, et al. Among authors: rothenberg ml. J Clin Oncol. 1999 Feb;17(2):685-96. doi: 10.1200/JCO.1999.17.2.685. J Clin Oncol. 1999. PMID: 10080615 Clinical Trial.
150 results